Introduction {#S0001}
============

General anesthesia is a medically induced state of low reactivity consciousness which is similar to natural sleep.[@CIT0001] Some studies found that general anesthesia as an independent risk factor could result in a desynchronization of the circadian time structure and cause postoperative sleep disorders characterized by reduced rapid eye movement (REM) and slow wave sleep (SWS),[@CIT0002] which have signiﬁcant deleterious impacts on postoperative outcomes, such as postoperative fatigue, severe anxiety and depression, emotional detachment and delirium, and even pain sensitivity or postoperative pain of patients.[@CIT0003],[@CIT0004] Clinical trials have already proved that intraoperative use of dexmedetomidine (DEX) for general anesthesia, a highly selective alpha-2 adrenergic agonist, was able to improve sedative and analgesic effects, reduce the incidence of postoperative delirium and promote sleep quality.[@CIT0005]--[@CIT0010] However, Tan et al reported that with the deeper sedative state provided by DEX in the daytime, the elderly male patients undergoing TURP under spinal anesthesia suffered worse sleep on the night of surgery.[@CIT0011] Thus, what the effect of intraoperative using DEX at different time periods under general anesthesia on postoperative sleep quality and pain will be needs further study. Based on these considerations, we sought to answer two questions in this study: What is the effect of using DEX during daytime operation or nighttime operation under general anesthesia on postoperative sleep quality of patients?What is the difference between intraoperative using DEX at different time periods on postoperative pain of patients under general anesthesia?

Materials And Methods {#S0002}
=====================

This study was approved by Human Research Ethical Committee of Shengjing Hospital, Shenyang, Liaoning Province, China (IRB registration number 2017PS29K) and was compliant with the Declaration of Helsinki. Written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at clinicaltrials.gov (NCT03990987).

Participants {#S0002-S2001}
------------

Patients who underwent elective laparoscopic abdominal surgeries under general anesthesia at Shengjing Hospital of China Medical University were enrolled in this study if they met the following inclusion criteria: age between 30 and 55 years and American Society of Anaesthesiologists (ASA) physical status I or II. Exclusion criteria included cardiovascular disease, long-term use of analgesic, preoperative heart rate (HR) less than 50 beats/min, second- or third-degree atrioventricular block, use of sleep-promoting medications, sleep disorder, sleep apnea syndrome, history of abnormal operation or anesthesia recovery, psychosis or a patient with a language communication disorder, did not provide informed consent.

Sample Size {#S0002-S2002}
-----------

Sample size calculation was based on the primary outcome of subjective sleep quality between the two groups. According to our preliminary study, the most difference of subjective sleep quality in the two groups was 0.8. So the estimated variability we chose was 0.8 between the two groups, and the standard deviation was 1.1; then we calculated the size of the sample, and twenty-nine patients for each group were required, assuming a two-sided Type I error (α) of 0.05 and a power of 80%. Potential loss was expected during follow-up or due to drop out; therefore, a total of 75 patients were enrolled in this study.

General Anesthesia {#S0002-S2003}
------------------

Before the operation, all patients fasted for 8--12 hrs. Upon arriving in the operating room, standard monitoring, including an electrocardiogram, non-invasive blood pressure (NIBP), heart rate (HR) and peripheral oxygen saturation (SpO~2~), were recorded using a multifunctional monitor (Draeger Inﬁnity Delta; Draeger Medical System Inc., Luebeck, Germany). General anesthesia was induced with propofol (2 mg/kg), sufentanil (0.2 μg/kg) and cisatracurium (0.15 mg/kg). After adequate jaw relaxation was attained, tracheal intubation was performed, and each patient was mechanically ventilated with a tidal volume and ventilation rate adjusted to maintain the pressure of end-tidal carbon dioxide (ETCO2) at 35--45 mmHg. Intravenous infusion was switched to a maintenance syringe pump at rate of 100 μg/kg/min for propofol, 0.15--0.2 μg/kg/min for remifentanil and 0.2--0.7 μg/kg/h for DEX, and together with inhaled 50% air and 50% oxygen (O~2~) at a fresh gas ﬂow rate of 2L/min. Cisatracurium (0.05 mg/kg) was intermittently used for muscle relaxation. The anesthesiologist adjusted the intravenous speed of remifentanil and DEX according to hemodynamic parameters and BIS (BIS monitor; Aspect Medical System, Newton, MA). The BIS was maintained between 40 and 55 during the operation. Ten minutes before the end of the surgery, all anesthetic infusions were stopped, and after extubating, the patients were transferred to the PACU for continuous monitoring.

Study Protocol And Measurements {#S0002-S2004}
-------------------------------

Seventy-five patients were assigned to the Day Group (D Group, 8:00--12:00) (n = 37) and the Night Group (N Group, 18:00--22:00) (n = 38), using a computer-generated randomized table. Patients received propofol, remifentanil and DEX for general anesthesia maintenance. After the operation, the PCA system was attached, and the patients were instructed in its use. The PCA system (sufentanil 100 μg diluted into 100 mL) was programmed to deliver a continuous dosage of sufentanil 0.02 μg kg^−1^ h^−1^ and a bolus dose of 0.02 μg/kg, with a 10-mins lockout interval. Finally, the patients were discharged from PACU to quiet ward where NIBP, SPO2 and HR were monitored.

BIS, mean arterial pressure (MAP) and HR of each patient were recorded at 5 mins after entering the operation room (T0); intubation (T1); 5 mins after intubating (T2); at the end of the operation (T3); extubation (T4); 5 mins after extubating (T5). And the total dose of remifentanil and DEX of both groups during the operation was recorded.

The Portable Sleep Monitor (PSM, PSM100A; Sealand Technology (Chengdu) Co. Ltd) was performed on the following 3 nights from 23 PM to 6 AM: the night before surgery (Sleep 1), the first night after surgery (Sleep 2) and the third night after surgery (Sleep 3). Sleep variables, such as sleep efficiency (the ratio of total sleep time/total recording time), the Athens insomnia scale (AIS) subjective sleep quality, the percentage of REM sleep, Unstable sleep and Stable sleep were recorded and analyzed by sleep laboratory staff who was blinded to patients\' information. Postoperative pain scores were evaluated by Visual analogue scale (VAS) score,[@CIT0012] which indicated that 0 was considered painless, and a score of 10 was considered as intense pain. Scores of 4 and below were considered mild pain (pain does not affect sleep), and scores of 5 to 6 were considered moderate pain (pain influences sleep, but the patients can still fall asleep). Scores of 7 and above were considered severe pain (due to the pain, the patient is unable to sleep or wakes up). Patients were encouraged to push the analgesic-demand button when they experienced signiﬁcant pain (VAS \>4 at rest). VAS was measured at 1, 6, 24, 48 hrs, postoperatively. Adverse effects such as hypotension, bradycardia, nausea and vomiting and hypoxemia were also treated accordingly.

Statistical Analysis {#S0002-S2005}
--------------------

SPSS 20.0 statistical software (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 6.0 software were used for data analysis. The Kolmogorov--Smirnov test was used to assess the distribution of variables. Continuous data were analyzed by using independent-samples Student's *t*-test and represented as mean ± standard deviation. For statistical analysis of sleep measures, AIS and sleep efficiency, independent-samples Student's *t*-test and the Wilcoxon rank-sum test were used. One-way analysis of variance (ANOVA) followed by Bonferroni correction was used for multiple comparisons. *P* \< 0.05 was considered to be statistically significant.

Results {#S0003}
=======

We initially assessed 93 patients for eligibility to participate in our study ([Figure 1](#F0001){ref-type="fig"}); of these, 12 patients refused to participate, 6 patients did not meet the inclusion criteria and the remaining 75 patients enrolled to the study. Following the completion of the study, 7 patients in the D Group were excluded from the study: 3 patients failed sleep monitoring due to detachment of electrode, 3 patients failed sleep monitoring due to allergic reaction to electrode paste and 1 patient received rescue analgesia. Eight patients in the N Group were excluded from the study: 4 patients failed sleep monitoring due to detachment of electrode, 2 patients failed sleep monitoring due to allergic reaction to electrode paste and 2 patients received rescue analgesia. Finally, the data from 30 patients in the D Group and 30 patients in the N Group were analyzed in the present study.Figure 1Flow-chart showing included and excluded patients.

General Conditions Of The Study Groups {#S0003-S2001}
--------------------------------------

There were no statistically significant differences (P \> 0.05) for age, weight, duration of anesthesia (mins), duration of surgery (mins) and estimated blood loss (mL) among the study groups. However, the extubation time of patients in the N Group was longer than that of patients in the D Group (P \< 0.001) ([Table 1](#T0001){ref-type="table"}).Table 1Baseline Characteristics Of Patients In The Day Group And The Night GroupDay GroupNight Group*P*Age (years)42.13±7.143.43±6.30.454Weight (kg)60.47±7.562.40±7.00.305Intraoperative data Duration of anesthesia (mins)94.13±20.192.60±11.00.715 Duration of surgery (mins)88.47±20.888.23±11.00.957 Extubation time (mins)7.5±1.89.2±1.7\<0.001 Estimated blood loss (mL)56.43±16.258.93±12.60.507[^1]

Anesthesia-Related Information Duration The Operation {#S0003-S2002}
-----------------------------------------------------

Patients in the N Group had statistically lower BIS values than those in the D Group from T1 to T5 (46.43±2.6 vs 51.73±3.4, 49.13±2.1 vs 51.50±3.0, 54.33±2.4 vs 59.03±3.3, 70.57±4.0 vs 74.77±4.1, 80.10±2.8 vs 83.17±4.0) ([Figure 2A](#F0002){ref-type="fig"}). There were no significant differences with respect to the baseline MAP and HR at T~0~ between the two groups. Furthermore, we observed sharp increases in MAP and HR evoked by intubation. Subsequently, MAP and HR were maintained at lower levels than baseline to extubation. And, patients in the N Group showed obvious lower levels in MAP and HR from T1 to T5 than patients in the D Group ([Figure 2B](#F0002){ref-type="fig"} and [C](#F0002){ref-type="fig"}, P \< 0.05, respectively).Figure 2BIS, Heart rate (HR) and Mean arterial pressure (MAP) during the operation. (**A**) Intraoperative BIS at different time points; (**B**) intraoperative MAP at different time points; (**C**) intraoperative HR at different time points; \* vs the Night Group: P \< 0.05; \*\* vs the Night Group: P \< 0.001. T0: 5 mins after entering the operation room; T1: Intubation; T2: 5 mins after intubating; T3: At the end of the operation; T4: Extubation; T5: 5 mins after extubating.

Intraoperative Dosage Of Remifentanil And DEX Of Study Groups {#S0003-S2003}
-------------------------------------------------------------

The total dose of DEX in the N Group was significantly less than that in the D Group (55.63±7.2 vs 61.91±11.3) ([Table 2](#T0002){ref-type="table"}, P = 0.013). And the total dose of remifentanil in the N Group also showed significantly less than those in the D Group (0.50±0.1 vs 0.66±0.1) ([Table 2](#T0002){ref-type="table"}, P \< 0.001).Table 2Total Dose Of Dexmedetomidine And Remifentanil Of Patients In The Day Group And The Night GroupDay GroupNight Group*P*Dexmedetomidine (μg)61.91±11.355.63±7.20.013Remifentanil (mg)0.66±0.10.50±0.1\<0.001[^2]

Postoperative Sleep Quality {#S0003-S2004}
---------------------------

Patients suffered from obvious sleep disturbance after surgery. Compared to Sleep 1, a lower sleep efficiency and a higher AIS subjective sleep quality were presented at Sleep 2 (71.97±2.8 vs 84.85±3.5 and 4.63±1.0 vs 2.23±0.8, P \< 0.001, respectively) and Sleep 3 (78.08±3.0 vs 84.85±3.5 and 3.87±0.9 vs 2.23±0.8, P \< 0.001, respectively) in the N Group ([Figure 3A](#F0003){ref-type="fig"} and [B](#F0003){ref-type="fig"}). Intraoperative administration of DEX for patients in the D Group could improve sleep quality with a higher sleep efficiency and a lower AIS subjective sleep quality than patients in the N Group at Sleep 2 (77.04±1.7 vs 71.97±2.8 and 3.73±1.0 vs 4.63±1.0, P \< 0.001, P = 0.001, respectively) and Sleep 3 (82.52±3.6 vs 78.08±3.0 and 2.87±0.7 vs 3.87±0.9, P \< 0.001, respectively) ([Figure 3A](#F0003){ref-type="fig"} and [B](#F0003){ref-type="fig"}). The sleep stages distribution is shown in [Figure 4](#F0004){ref-type="fig"}. Compared with Sleep 1, Unstable sleep time was longer at Sleep 2 (52.05±3.2 vs 42.35±4.2) and Sleep 3 (46.45±2.8 vs 42.35±4.2) in the N Group and Unstable sleep time was also longer at Sleep 2 and Sleep 3 in the D Group than that in the N Group (57.66±4.6 vs 52.05±3.2 and 53.94±4.3 vs 46.45±2.8, P \< 0.001, respectively) ([Figure 4C](#F0004){ref-type="fig"}). Compared with Sleep 1 in the D Group, there were significant decreases in REM sleep and Stable sleep at Sleep 2 (24.28±2.4 vs 19.06±1.9 and 33.38±4.6 vs 28.89±3.2, P \< 0.001, respectively) and Sleep 3 (24.28±2.4 vs 21.67±1.9 and 33.38±4.6 vs 31.88±3.1, P \< 0.001 and P \< 0.05, respectively) ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}) and there were marked lower REM sleep and Stable sleep in the N Group than that in the D Group at Sleep 2 (15.83±1.8 vs 19.06±1.9 and 26.51±5.0 vs 28.89±3.2 P \< 0.001, P = 0.032, respectively) and Sleep 3 (18.13±1.9 vs 21.67±1.9 and 27.93±5.0 vs 31.88±3.1, P \< 0.001, respectively) ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}).Figure 3Comparison of sleep efficiency and the AIS scores between the Day Group and the Night Group. (**A**) Sleep efficiency; (**B**) AIS. AIS: The Athens Insomnia Scale; Sleep efficiency: the ratio of total sleep time/total recording time. Sleep 1: the night before surgery; Sleep 2: the first night after surgery; Sleep 3: the third night after surgery. In the same group, \*\* vs Sleep 1: P \< 0.001. At the same point, \# vs the Day Group: P \< 0.05.Figure 4Comparison of the percentage of sleep stages distribution between the Day Group and the Night Group. (**A**) REM; (**B**) Stable sleep; (**C**) Unstable sleep. REM: Rapid eye movement; Sleep 1: the night before surgery; Sleep 2: the first night after surgery; Sleep 3: the third night after surgery. In the same group, \* vs Sleep 1: P \< 0.05; \*\* vs Sleep 1: P \< 0.001. At the same point, \# vs the Day Group: P \< 0.05.

Postoperative VAS Evaluation {#S0003-S2005}
----------------------------

After surgery, all patients received sufentanil-based PCA pump. Postoperative pain was assessed with VAS. During the first 48 hrs, patients in the N Group had a higher VAS score compared to the D Group at 1, 6, 24, 48 hrs after surgery (2.97±0.9, 2.17±0.8, 1.47±0.7 and 1.07±0.5 vs 2.60±1.0, 1.77±0.6, 0.87±0.6 and 0.63±0.6, P \< 0.05, respectively) and a higher pump press numbers (36.03±2.1 vs 28.90±3.3, P \< 0.05) ([Figure 5A](#F0005){ref-type="fig"} and [B](#F0005){ref-type="fig"}).Figure 5Postoperative VAS and PCA pump press numbers. (**A**) Postoperative VAS between the Day Group and the Night Group. (**B**) Postoperative PCA pump press number between the Day Group and the Night Group. VAS: Visual analogue scale \* vs the Day Group: P \< 0.05.

Discussion {#S0004}
==========

Our result confirmed that patients would suffer from obvious sleep disturbance after receiving general anesthesia. And the effect of the nighttime operation on postoperative sleep disturbance was more obvious than that of daytime operation. However, intraoperative use of DEX during the daytime operation could better improve the sleep efficiency and subjective sleep quality and promote the analgesia property of sufentanil-based PCA than intraoperative use of DEX during the nighttime operation.

In the current study, our data demonstrated that there was severe sleep disturbance with lower sleep efficiency and higher AIS score after surgery, which was manifested as decreased percentage of REM and Stable sleep. Moreover, it seems that the decrease of postoperative REM and Stable sleep after the nighttime operation were larger than those after the daytime operation and the extubation time at night was also longer than that during the day. This could be explained as the general anesthetics may be relatively overdose at night, which was consistent with Chassard D's study that depending on the time-of-day of administration, the doses and duration of action of general anesthetics during the day were different from that at night.[@CIT0013]

Akeju et al have stated that pharmacological induction of biomimetic sleep may significantly reduce drug-induced neurocognitive dysfunction.[@CIT0014] Insight from these advances suggests that α2 adrenergic receptor agonist medications may closely pattern the activity of arousal nuclei similar to non-REM sleep.[@CIT0015] In our study, we found that the dosage of DEX in the D Group was significantly more than that in the N Group, and the Unstable sleep of patients in the D Group increased more obviously than patients in the N Group, which was likely associated with DEX's pharmacologic activation of the endogenous sleep-promoting pathway to produce a state resembling physiologic stage N2 sleep[@CIT0016] and indicated its beneficial effect focusing on improving sleep quality and reducing sleep fragmentation. Meanwhile, the sleep efficiency and subjective sleep quality in the D Group were better than those in the N Group, which was consistent with the previous conclusion that though DEX has no improvement on REM and Stable sleep, it could prolong the total sleep time and ameliorate the sleep architecture by increasing Unstable sleep.[@CIT0008]

Previous study found that patients sedated with DEX during the operation under spinal anesthesia may have experienced worse postoperative sleep. Their finding may because patients were awake during the operation, with the deeper sedative state provided by DEX, the natural sleep cycle of patients was disturbed in the daytime and then have worse effect on the night after surgery, which was different from our study that involved patients under general anesthesia.[@CIT0011]

Previous study also indicated that postoperative sleep disturbance could lead to hyperalgesia.[@CIT0017] Effective postoperative pain relief might break the vicious cycle and have a positive effect on the recovery of postoperative sleep disturbance. Among the various available protocols for postoperative pain management, opioids are widely used. Some studies indicated that opioids also have negative impact on sleep through inhibition of REM and Stable sleep, which could aggravate the influence of postoperative sleep disorders on patients.[@CIT0018] Clinical studies have already confirmed that the potential of DEX as an adjuvant for pain treatment could contribute to the recovery-promoting effect following different kinds of operations and this use suggests that DEX might be a new drug for surgery-induced acute pain control.[@CIT0019]--[@CIT0021] In the present study, we combined DEX with propofol and remifentanil to maintain the general anesthesia, and we found patients from the D Group had lower VAS score and less PCA pump press numbers than those in the N Group during the first 48 hrs after surgery, which showed that intraoperative DEX was helpful in relieving postoperative pain and postoperative pain relief was more effective among patients receiving daytime operation than those receiving nighttime operation. And through administering a continuous infusion during the operation, we did not see a significant decrease in HR or MAP between the two groups, which were consistent with previous reports which indicated that intraoperative DEX provided more stable anesthesia without changing hemodynamic characteristics, and promoted quality of recovery from surgeries.[@CIT0022]--[@CIT0024]

There might be several limitations in the present study. First, only one preoperative night of monitoring is recorded in our design; the unusual situation might cause changes in the PSM. Second, though nocturnal interventions were reduced as much as possible, we could not completely rule out factors that might have negative effects on the quality of sleep such as light, noise or interruptions due to nursing care. Third, the patients enrolled in this study were 30--55 years old; the effect of DEX on other patients such as elderly patients or children should be further investigated. Fourth, this is a single-center analysis character focusing only on one specific hospital and one population, and multicenter experiment should be further studied.

Conclusion {#S0005}
==========

Using DEX during the daytime operation could better improve postoperative sleep efficiency and subjective sleep quality and promote the analgesia property of sufentanil-based PCA than intraoperative use of DEX during the nighttime operation. Our study recommended that the intraoperative dose of DEX and the dose of postoperative analgesics for the nighttime operation should be increased appropriately compared with those for the daytime operation.
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